Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142683 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9AHPGDNPC1TP53 | |
| SCHEMBL20456696 | 0.93 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9AHPGDNPC1TP53 | |
| SCHEMBL20456697 | 0.93 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9AHPGDNPC1TP53 | |
| SCHEMBL6627348 | 0.89 | HPGD (0.42) | SMN1; SMN2RAB9AHPGDNPC1TP53 | |
| SCHEMBL11187096 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2RAB9AHPGDNPC1TP53 | |
| SCHEMBL8915983 | 0.80 | — | — | |
| SCHEMBL1579651 | 0.80 | — | — | |
| SCHEMBL1579653 | 0.80 | — | — | |
| SCHEMBL14017948 | 0.78 | — | — | |
| Hexane SCHEMBL10378373 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9AHPGDNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318148-B1 | Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone | SK CORP (KR) | 2005-01-12 | — | — | EP | disclosed |
| US-6841688-B2 | Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone | SK CORPORATION (KR) | 2005-01-11 | — | — | US | disclosed |
| US-20030114693-A1 | Method of preparing optically pure (R) - or (S) - tetrahydrofuranyl ketone | SK CORPORATION | 2003-06-19 | — | — | US | disclosed |
| EP-1318148-A1 | Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone | SK Corporation (KR) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114693-A1 | Method of preparing optically pure (R) - or (S) - tetrahydrofuranyl ketone | DCXR, NISCH, NOP2 | SMN1; SMN2 1601/4885RAB9A 3642/4885HPGD 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.